Lb Pharmaceuticals Inc (LBRX) Institutional Ownership

Ownership Summary

Lb Pharmaceuticals Inc (NASDAQ:LBRX) is held by 77 institutional investors per 13F filings through March 2026.

• Their combined ownership stood at 100.1% of outstanding shares in March 2026, down from 311.8% in December 2025.
• Their total shares held in LBRX increased 18.94% quarter over quarter, and separately, investors owning Lb Pharmaceuticals stayed flat from a year ago.
• Of these 77 holders, 50 added to their stakes in Lb Pharmaceuticals, 15 trimmed positions, and 12 made no changes.
• In total, institutional investors held 28.28Mn shares in Lb Pharmaceuticals as of March 2026, up by 4.5Mn shares quarter on quarter, and with no net change year over year.
• Deep Track Capital, LP is the top holder of Lb Pharmaceuticals as of March 31, 2026, with 3.35Mn shares representing 11.87% of outstanding stock.
• The most significant purchases of LBRX for the quarter ending March 2026 came from Caligan Partners LP (1.44Mn), VANGUARD CAPITAL MANAGEMENT LLC (894.65K), Nantahala Capital Management, LLC (377.89K), Spruce Street Capital LP (370.57K), Nan Fung Group Holdings Ltd (330.66K).
• The largest sellers of Lb Pharmaceuticals for the quarter ending March 2026 were Logos Global Management LP (285.0K), JENNISON ASSOCIATES LLC (283.64K), Goldman Sachs Group Inc (242.43K), Jpmorgan Chase & Co (183.91K), Ameriprise Financial Inc (85.24K).
• According to Business Quant data, leading holders of LBRX for March 2026 are Deep Track Capital, LP (3.35Mn), BlackRock, Inc. (2.47Mn), RA CAPITAL MANAGEMENT, L.P. (2.21Mn), TCG Crossover Management, LLC (1.84Mn), Commodore Capital LP (1.5Mn), Caligan Partners LP (1.44Mn), Jpmorgan Chase & Co (1.43Mn), Spruce Street Capital LP (1.38Mn), Trails Edge Capital Partners, LP (1.32Mn), Nantahala Capital Management, LLC (1.05Mn).